LPLaurel C. Preheim

Laurel C. Preheim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurel C. Preheim has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Keith M. Olsen

    College of Pharmacy, University of Nebraska Medical Center, Omaha 68198, USA

    3 shared publications
  • Martha J. Gentry-Nielsen

    2 shared publications
  • Mary U. Snitily

    Colleges of Pharmacy,1 Medicine, University of Nebraska Medical Center, 600 South 42nd St., Omaha, Nebraska 68198,2 Infectious Diseases Section, Veterans Affairs Medical Center,3 Veterans Affairs Medical Center, 4101 Woolworth Avenue, Omaha, Nebraska 68105,4 Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 681785

    2 shared publications
  • Mei Yue

    Colleges of Pharmacy,1 Medicine, University of Nebraska Medical Center, 600 South 42nd St., Omaha, Nebraska 68198,2 Infectious Diseases Section, Veterans Affairs Medical Center,3 Veterans Affairs Medical Center, 4101 Woolworth Avenue, Omaha, Nebraska 68105,4 Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 681785

    2 shared publications
  • Martha Gentry-Nielsen

    Colleges of Pharmacy,1 Medicine, University of Nebraska Medical Center, 600 South 42nd St., Omaha, Nebraska 68198,2 Infectious Diseases Section, Veterans Affairs Medical Center,3 Veterans Affairs Medical Center, 4101 Woolworth Avenue, Omaha, Nebraska 68105,4 Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 681785

    1 shared publication
  • Martin H. Ellbogen

    Infectious Diseases Section, Omaha, NE 68105, USA

    1 shared publication

Latest Publications

  • Open Access

    Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia

    by Keith M. Olsen, Martha Gentry-Nielsen, Mei Yue, Mary U. Snitily, Laurel C. Preheim

    This investigation compared the effect of ethanol on fluoroquinolone antibiotic efficacy and pharmacodynamics in an ethanol-fed rat model of pneumococcal pneumonia. Male Sprague-Dawley rats received a liquid diet containing 36% of total calories as ethanol. Paired controls (pair-fed controls) were fed a liquid diet without ethanol or received rat chow. Diets began 7 days before and continued for 10 days after transtracheal infections with 10 times the 50% lethal dose of type 3 Streptococcus pneumoniae . Beginning 18 h after infection, the rats received once daily subcutaneous phosphate-buffered saline, levofloxacin, moxifloxacin, or trovafloxacin at 50 or 100 mg/kg of body weight. White blood cell counts were determined, blood samples were collected for culture, and mortality was recorded. Additional rats were killed on day 5 for pharmacodynamic studies and quantitative cultures of bronchoalveolar lavage fluid. Bacteremia occurred by day 3 in 20 of 22 untreated rats. All 22 untreated rats died by day 9. Moxifloxacin treatment was effective in all diet groups at both the 50- and 100-mg/kg doses. In contrast, 50-mg/kg doses of levofloxacin and trovafloxacin improved survival in ethanol-fed rats but were ineffective in chow-fed rats. High-dose trovafloxacin at 100 mg/kg was associated with increased mortality in pair-fed rats. The free-fraction area under the concentration-time curve/MIC ratio exceeded 50 with all antibiotics in the ethanol group but dropped below 30 with levofloxacin and trovafloxacin in the pair- and chow-fed rats, with higher mortality. Achievement of adequate antibiotic-free fraction area under the concentration-time curve/MIC ratios helps overcome ethanol-induced immune defects induced in experimental pneumococcal pneumonia.


  • Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia

    by Laurel C. Preheim, Keith M. Olsen, Mei Yue, Mary U. Snitily, Martha J. Gentry-Nielsen


  • Open Access

    Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.

    by Martin H. Ellbogen, Keith M. Olsen, Martha J. Gentry-Nielsen, Laurel C. Preheim

    Encapsulation of ciprofloxacin in sterically stabilized liposomes results in a prolonged circulation time and improved pharmacokinetics. Liposome-encapsulated ciprofloxacin was compared with conventional ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. Male Sprague–Dawley rats were infected transtracheally with type 3 Streptococcus pneumoniae and then treated with intravenous ceftriaxone (100 mg/kg), ciprofloxacin (40 or 80 mg/kg) or liposomal ciprofloxacin (40 or 80 mg/kg) administered once or twice daily for 3 days. White blood counts, development of bacteraemia and mortality were measured for 10 days. Antibiotic concentrations in serum, lung lavage fluid and white blood cells recovered from lung lavage fluid were determined. Liposomal ciprofloxacin concentrations were significantly higher in serum and lavage fluid compared with conventional ciprofloxacin, resulting in greater area under the serum concentration–time curve and maximum serum concentration. Despite these higher concentrations, survival rates were similar between groups treated with equivalent doses of liposomal ciprofloxacin versus ciprofloxacin. When antibiotics were given once daily, ceftriaxone was more effective than either form of ciprofloxacin.